Cargando…

Negative Hyperselection of Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer Who Received Panitumumab-Based Maintenance Therapy

PURPOSE: We assessed the prognostic/predictive role of primary tumor sidedness and uncommon alterations of anti–epidermal growth factor receptor (EGFR) primary resistance (primary resistance in RAS and BRAF wild-type metastatic colorectal cancer patients treated with anti-EGFR monoclonal antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morano, Federica, Corallo, Salvatore, Lonardi, Sara, Raimondi, Alessandra, Cremolini, Chiara, Rimassa, Lorenza, Murialdo, Roberto, Zaniboni, Alberto, Sartore-Bianchi, Andrea, Tomasello, Gianluca, Racca, Patrizia, Clavarezza, Matteo, Adamo, Vincenzo, Perrone, Federica, Gloghini, Annunziata, Tamborini, Elena, Busico, Adele, Martinetti, Antonia, Palermo, Federica, Loupakis, Fotios, Milione, Massimo, Fucà, Giovanni, Di Bartolomeo, Maria, de Braud, Filippo, Pietrantonio, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2019
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864846/ https://www.ncbi.nlm.nih.gov/pubmed/31539295 http://dx.doi.org/10.1200/JCO.19.01254

Ejemplares similares

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials
por: Fucà, Giovanni, et al.
Publicado: (2020)

Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study
por: Raimondi, A., et al.
Publicado: (2021)

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer
por: Randon, Giovanni, et al.
Publicado: (2019)

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients
por: Battaglin, Francesca, et al.
Publicado: (2018)

Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O(6)-Methylguanine–DNA Methyltransferase–Silenced Metastatic Colorectal Cancer: The MAYA Trial
por: Morano, Federica, et al.
Publicado: (2022)

Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study
por: Cremolini, Chiara, et al.
Publicado: (2019)

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study
por: Cremolini, Chiara, et al.
Publicado: (2017)

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study
por: Pietrantonio, Filippo, et al.
Publicado: (2016)

Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With RAS/BRAF Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO
por: Rossini, Daniele, et al.
Publicado: (2022)

Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Fucà, Giovanni, et al.
Publicado: (2021)

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable RAS and BRAF wild-type metastatic colorectal cancer
por: Borelli, Beatrice, et al.
Publicado: (2018)

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials
por: Cremolini, Chiara, et al.
Publicado: (2018)

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer
por: Oddo, Daniele, et al.
Publicado: (2017)

AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer
por: Antoniotti, Carlotta, et al.
Publicado: (2020)

Panitumumab‐based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials
por: Modest, Dominik Paul, et al.
Publicado: (2019)

Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2022)

Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients
por: Crisafulli, Giovanni, et al.
Publicado: (2019)

Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan
por: Pietrantonio, Filippo, et al.
Publicado: (2020)

BRAF-mutated metastatic colorectal cancer between past and future
por: Cremolini, Chiara, et al.
Publicado: (2015)

The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2019)

Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancers
por: Volpi, Chiara Costanza, et al.
Publicado: (2020)

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis
por: Cremolini, Chiara, et al.
Publicado: (2017)

Nomogram to predict the outcomes of patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
por: Pietrantonio, Filippo, et al.
Publicado: (2021)

Identification and characterization of a novel SCYL3-NTRK1 rearrangement in a colorectal cancer patient
por: Milione, Massimo, et al.
Publicado: (2017)

Gain of ALK Gene Copy Number May Predict Lack of Benefit from Anti-EGFR Treatment in Patients with Advanced Colorectal Cancer and RAS-RAF-PI3KCA Wild-Type Status
por: Pietrantonio, Filippo, et al.
Publicado: (2014)

Author response to Colle et al
por: Fucà, Giovanni, et al.
Publicado: (2021)

Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective
por: Prisciandaro, Michele, et al.
Publicado: (2022)

Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study
por: Lonardi, Sara, et al.
Publicado: (2021)

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
por: Cremolini, Chiara, et al.
Publicado: (2017)

Long-Term Oncological and Functional Outcomes after Laparoscopic Partial Nephrectomy with Hyperselective Embolization of Tumor Vessels in a Hybrid Operating Room
por: Frantz, Ulysse, et al.
Publicado: (2023)

CK7 and consensus molecular subtypes as major prognosticators in (V600E)BRAF mutated metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2019)

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial
por: Di Bartolomeo, Maria, et al.
Publicado: (2019)

Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups
por: Centonze, Giovanni, et al.
Publicado: (2020)

DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer
por: Cremolini, Chiara, et al.
Publicado: (2017)

MGMT inactivation as a new biomarker in patients with advanced biliary tract cancers
por: Niger, Monica, et al.
Publicado: (2022)

Circulating Biomarkers in Advanced Colorectal Cancer Patients Randomly Assigned to Three Bevacizumab-Based Regimens
por: Martinetti, Antonia, et al.
Publicado: (2014)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2020)

Improved Prognostic Prediction in Never-Smoker Lung Cancer Patients by Integration of a Systemic Inflammation Marker with Tumor Immune Contexture Analysis
por: Milione, Massimo, et al.
Publicado: (2020)

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study
por: Raimondi, Alessandra, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8antsbn753uu3qcmgvd1rmjsub